Published in J Infect Dis on April 01, 1985
Establishment of a human T-cell clone cytotoxic for both autologous and allogeneic hepatocytes from chronic hepatitis patients with type non-A, non-B virus. Proc Natl Acad Sci U S A (1989) 0.85
Non-A, non-B hepatitis: dead ends or new horizons? Br Med J (Clin Res Ed) (1987) 0.75
Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy. Postgrad Med J (1990) 0.75
An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A (1968) 7.33
On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med (1975) 4.11
Serum hepatitis antigen (SH): rapid detection by high voltage immunoelectroosmophoresis. Science (1970) 4.00
Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci U S A (1991) 3.34
The role of circulating hepatitis B antigen/antibody immune complexes in the pathogenesis of vascular and hepatic manifestations in polyarteritis nodosa. J Clin Pathol (1974) 2.85
Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet (1974) 2.77
Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A (1982) 2.52
Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci U S A (1988) 2.47
Catenins and zonula occludens-1 form a complex during early stages in the assembly of tight junctions. J Cell Biol (1996) 2.37
Immunity in hepatitis C infection. J Infect Dis (1992) 2.28
Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet (1992) 2.25
Immunologic distinction between infectious and serum hepatitis. N Engl J Med (1970) 2.16
Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology (1978) 2.09
A serologic study of cytomegalovirus infections associated with blood transfusions. N Engl J Med (1971) 2.02
Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers. JAMA (1974) 1.92
Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen. Lancet (1973) 1.89
Role of serum hepatitis virus in chronic liver disease. Gastroenterology (1971) 1.84
Isolation of a simian immunodeficiency virus related to human immunodeficiency virus type 2 from a west African pet sooty mangabey. J Virol (1991) 1.82
Relation of Australia and SH antigens. Lancet (1968) 1.75
Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance. Gut (1976) 1.74
Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine (1986) 1.68
Hepatitis B "immune" globulin: effectiveness in prevention of dialysis-associated hepatitis. N Engl J Med (1975) 1.66
Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A (1989) 1.64
Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis (1993) 1.63
Regulated processing of hepatitis C virus core protein is linked to subcellular localization. J Virol (1997) 1.63
Familial clustering of hepatitis B infection. N Engl J Med (1973) 1.56
S.H. antigen and chronic liver disease. Lancet (1970) 1.51
Intrafamilial spread of asymptomatic hepatitis B. Am J Med Sci (1977) 1.48
Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin. Nature (1991) 1.47
Hepatitis B antigen and antibody in blood donors: an epidemiologic study. J Infect Dis (1973) 1.46
The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion (1990) 1.45
Gamma-glutamyltransferase as a potential surrogate marker for detection of the non-A, non-B carrier state. Vox Sang (1988) 1.44
The epidemiology of hepatitis B infections in Africa: results of a pilot survey in the Republic of Senegal. Am J Epidemiol (1973) 1.43
Prevalence of serum-hepatitis-related antigen (SH) in different geographic regions. Am J Trop Med Hyg (1970) 1.42
The epidemiology of serum hepatitis (SH) infections: a controlled study in two closed institutions. Am J Epidemiol (1971) 1.40
Sounding board. Use of hepatitis B immuneglobulin:reassessment needed. N Engl J Med (1978) 1.40
Virulent HIV strains, chimpanzees, and trial vaccines. Science (1999) 1.40
Virus-like particles in human plasma and serum: role of platelet lysosomes. J Natl Cancer Inst (1966) 1.39
Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. J Infect Dis (1987) 1.38
Production of albumin and other serum proteins by clonal cultures of normal human liver. Proc Natl Acad Sci U S A (1971) 1.38
The development of virus-free labile blood derivatives--a review. Eur J Epidemiol (1987) 1.33
Molecular cloning and characterization of onchocystatin, a cysteine proteinase inhibitor of Onchocerca volvulus. J Biol Chem (1992) 1.33
Role of immune complexes involving SH antigen in pathogenesis of chronic active hepatitis and polyarteritis nodosa. Lancet (1971) 1.30
Clinical signs of the pseudoexfoliation syndrome. Ophthalmology (1986) 1.29
Serum hepatitis specific antigen (SH) in commercial and volunteer sources of blood. Transfusion (1971) 1.29
Development and distribution of hemagglutinating antibody against the hepatitis B antigen in institutionalized populations. J Infect Dis (1972) 1.28
Hepatitis B antigen in wild-caught mosquitoes in Africa. Lancet (1972) 1.27
Preclinical diagnosis of pseudoexfoliation syndrome. Arch Ophthalmol (1987) 1.25
Identification of additional antigenic sites on Dane particles and the tubular forms of hepatitis B surface antigen. J Gen Virol (1976) 1.25
A case/control study of the association between primary liver cancer and hepatitis B infection in Senegal. Int J Cancer (1975) 1.24
Use of conserved sequences from hepatitis C virus for the detection of viral RNA in infected sera by polymerase chain reaction. Hepatology (1991) 1.23
Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood (1992) 1.22
Three different patterns of hepatitis C virus infection in chimpanzees. Hepatology (1992) 1.21
Hypericin as an inactivator of infectious viruses in blood components. Transfusion (1995) 1.19
Identification of an immunodominant epitope within the capsid protein of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 1.18
Role of arthropods in transmission of hepatitis-B virus in the tropics. Lancet (1973) 1.17
Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J Infect Dis (1998) 1.15
Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother (2001) 1.14
Detection of virus-associated antigen in serum and liver of patients with non-A non-B hepatitis. Lancet (1979) 1.14
The serum hepatitis related antigen (SH) in illicit drug users. Am J Epidemiol (1970) 1.13
Chronic liver disease in asymptomatic narcotic addicts. Ann Intern Med (1972) 1.10
Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol (1998) 1.09
Detection of e antigen and antibody: correlations with hapatitis B surface and hepatitis B core antigens, liver disease, and outcome in hepatitis B infections. Gastroenterology (1976) 1.09
DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology (2001) 1.08
Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine (1997) 1.08
Electron microscopical and immunological observations on the serum-hepatitis (S.H.) antigen in primary biliary cirrhosis. Lancet (1970) 1.07
The serum hepatitis virus specific antigen (SH): a preliminary report of epidemiologic studies in an institution for the mentally retarded. Am J Epidemiol (1970) 1.07
Letter: Hepanosticon in screening for HBsAg. Lancet (1975) 1.07
Characterization of an Onchocerca volvulus cDNA clone encoding a genus specific antigen present in infective larvae and adult worms. Mol Biochem Parasitol (1991) 1.06
Full-genome sequence analyses of hepatitis B virus (HBV) strains recovered from chimpanzees infected in the wild: implications for an origin of HBV. Virology (2000) 1.06
Clinical trials of hepatitis B immune globulin. Development of policies and materials for the 1972-1975 studies sponsored by the National Heart and Lung Institute. N Engl J Med (1975) 1.06
Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. J Infect Dis (1999) 1.06
Cloning of a cysteine protease required for the molting of Onchocerca volvulus third stage larvae. J Biol Chem (1996) 1.05
Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis (1978) 1.05
Quantitative assays for evaluation of HTLV-III inactivation procedures: tri(N-butyl)phosphate:sodium cholate and beta-propiolactone. Cancer Res (1985) 1.04
Schistosoma infection inhibits cellular immune responses to core HCV peptides. Parasite Immunol (2005) 1.03
Electrn microscopic observations on virus-like particles associated with SH antigen. J Virol (1970) 1.02
Studies on delayed hypersensitivity to hepatitis B antigen in chimpanzees. Clin Exp Immunol (1974) 1.01
Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG. AIDS Res Hum Retroviruses (1992) 1.01
Transglutaminase-catalyzed reaction is important for molting of Onchocerca volvulus third-stage larvae. Antimicrob Agents Chemother (1995) 1.00